Buenos Aires, October 6, 2026. Argentine media is dedicating the Nobel Prize in Medicine, announced on Monday, October 5, to an explanation of optogenetics and what it changes for the understanding of the brain. Clarín, Perfil, and Ámbito quote American Karl Deisseroth, from Stanford, and Germans Peter Hegemann and Georg Nagel, distinguished for "light-activated ion channels and optogenetics".

Perfil tells the story of the origin of the prize with a simple question: how does a single-celled alga detect light to swim towards it? The daily newspaper emphasizes that the technique makes it possible to prove causality, i.e., to show that a specific group of neurons produces a given response, whereas we only knew which regions were activated. It quotes the formula that optogenetics makes it possible to map the brain "in a way we could only dream of".

Ámbito details the chronology: Hegemann and Nagel discover channelrhodopsin in Chlamydomonas, which opens to blue light; Deisseroth introduces the gene into rat neurons, publishes in 2005, and then gets the switch to work in the brains of living mice two years later. The title evokes possible advances against Parkinson's, epilepsy, and depression, and the text specifies Deisseroth's age, 54, born in Boston.

Clarín publishes two texts. The first is a general-audience explanatory piece: researchers introduce light-sensitive proteins into certain cells, then activate or deactivate these neurons with a light beam, which has made it possible to study movement, memories, and emotions. The second reprints an interview with Deisseroth by the AFP. The laureate explains that the brain has billions of cells with different functions and that "a way to distinguish them" was needed. He also emphasizes that in psychiatry, unlike cardiology, there was a lack of a good model of what really differs.

The coverage therefore remains centered on the science and its expected clinical applications, without local debate on research funding or the state of Argentine science. The laureates are presented through their background and university, and the Nobel Committee is quoted to describe the opening of "a new era in neuroscience".

Canberra, October 6, 2026. Australian media are treating the Nobel Prize in Physiology or Medicine, announced on Monday, October 5, at the Karolinska Institute in Stockholm, as the opening of Nobel Week, with the physics, chemistry, literature, peace, and economics prizes to come.

ABC News Australia and PerthNow report that American Karl Deisseroth, 54, from Stanford, and Germans Peter Hegemann, 71, from Humboldt University in Berlin, and Georg Nagel, 73, from the University of Wurtzbourg, are being recognized for their work on light-activated ion channels and optogenetics. The Nobel Committee, cited by ABC on X, estimates that the method "is now being used in laboratories around the world to reveal the brain's mysteries".

The two articles emphasize the scientific narrative, from origin to application. Peter Hegemann first studied how a single-celled green alga swims towards light. With Georg Nagel, he identified a protein that, when exposed to blue light, opens a channel and creates an electrical impulse; introducing it into other cells makes them sensitive to light. Karl Deisseroth then used the gene of this protein to manufacture a light-controlled switch in the brains of living mice.

PerthNow quotes Jeremy Berg, from the University of Pittsburgh, who sees optogenetics as "a very precise set of tools for doing experiments about how the brain works that are pretty hard to do any other way". Having worked at the National Institutes of Health in the early 2000s, he recalls that the agency had funded Karl Deisseroth for this vision, which has unfolded "pretty much spot-on".

Brussels, 6 October 2026. The Belgian press welcomes the 2026 Nobel Prize in Medicine through the prism of brain and eye health. Awarded on Monday, 5 October to American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel, the prize rewards optogenetics, a technique that allows for the activation or deactivation of specific neurons with light.

VRT NWS covers the day live and explains in simple terms: the discovery was born out of the curiosity of Peter Hegemann, a biophysicist, who wanted to know why a green alga reacts so quickly to light. The Flemish media outlet talks about a "light switch" in nerve cells, validated in mice and rats. It mainly retains the insight provided into depression, addiction, anxiety, and dementia. The channel also invites science journalist Koen Wauters to explain in the Journal how these studies can help patients.

Neurophysiologist Wim Vanduffel (KU Leuven) provides the Belgian academic guarantee: "No one had ever thought that fundamental research on algae would lead to such a breakthrough." VRT emphasizes that the technique is used in laboratories around the world and recalls the amount: 12 million Swedish crowns per laureate, approximately one million euros.

La Libre Belgique, on the Francophone side, focuses on clinical applications, particularly degenerative diseases of the retina, in its title. It quotes the jury, which mentions a technology that allows us to understand "how nerve cells influence our memories, emotions, and behaviors," with millisecond precision using light beams. The newspaper also notes that some saw the pioneers of GLP-1, the origin of Ozempic or Wegovy, as big favorites.

Ottawa, October 6, 2026. The Canadian press reports on the Nobel Prize in Physiology or Medicine, announced on Monday, October 5, in Stockholm, emphasizing the genesis of the tool. The Globe and Mail opens with "a discovery that began with algae and transformed into a powerful method for studying the brain." Karl Deisseroth, from Stanford University, Peter Hegemann, from Humboldt University of Berlin, and Georg Nagel, from the University of Würzburg, are being rewarded for their "discoveries concerning light-activated ion channels and optogenetics."

The Toronto daily retraces the history since the 1980s. Peter Hegemann, a biophysicist at the Max-Planck Institute of Biochemistry in Martinsried, was then interested in the ability of pond algae to sense sunlight and react to it, which allows them to regulate photosynthesis. This phenomenon led to channelrhodopsins, proteins that algae use to convert light into electrical signals. Hegemann found the associated gene, which Georg Nagel managed to produce in frog oocytes to study its function. Abdel El Manira, a committee member, is quoted: the two researchers "had discovered the switch that neuroscientists had long dreamed of."

CBC News emphasizes the scope for understanding the brain. Thomas Perlmann, Secretary General of the Nobel Assembly at the Karolinska Institute, explains that the method allows for turning on or off the activity of individual nerve cells in a living brain, and that it is used in laboratories around the world. He reports that the three laureates, surprised, said they were honored to receive the prize together. Anna Wedell, a geneticist and committee member, judges that a new era is opening in neuroscience, but that it is only the beginning: "For the first time, we can start to understand how the brain processes information."

Berne, October 6, 2026. The Nobel Prize in Physiology or Medicine opens the week of the Nobels: the committee meeting in Stockholm on Monday, October 5, awarded it to American Karl Deisseroth, a professor at Stanford, and Germans Peter Hegemann, from the University of Berlin, and Georg Nagel, from the University of Wurtzbourg. The committee rewards them "for their discoveries concerning light-activated ion channels and optogenetics".

The Swiss press first emphasizes the mechanism. SRF explains that optogenetics makes it possible to turn cells on or off, most often neurons, using light, including in living tissues and in freely moving animals. Hegemann and Nagel discovered channelrhodopsine, a protein that makes cells sensitive to light; Deisseroth introduced its gene into rat neurons, which he was thus able to activate with light.

The Temps gives the floor to Abdel El Manira, a member of the Nobel Committee: observing brain activity is not enough to understand how "ninety billion neurons" produce a behavior or a memory, it is necessary "to establish cause-and-effect relationships". According to the committee, the tool has already been used to identify neural circuits of pain, social behaviors, thirst, food, and reward.

The Geneva daily adds a national reference point: Peter Hegemann and Georg Nagel had received the Louis-Jeantet Foundation's Prize for Encouragement of European Biomedical Research in 2013. Switzerland thus positions itself as an observer who had early on recognized the work of the laureates.

Bogotá, October 6, 2026. The Nobel Prize in Physiology or Medicine was awarded on Monday, October 5, to American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel. Portafolio and El Colombiano, which reproduce the same dispatch, focus on the use of optogenetics: a discipline that allows us to understand how certain cells contribute to learning, fear, addiction, and movement.

The Colombian press emphasizes the therapeutic scope. According to Portafolio, the work of Deisseroth, a psychiatrist and neurologist, and his colleagues "could one day" lead to treatments for neurological and sensory disorders, such as Parkinson's disease and epilepsy. In clinical medicine, researchers use the method to try to restore the vision of people with impaired vision. The Nobel Committee, cited by the newspaper, states that the researchers were able to reveal the neural circuits that control memories, feelings, and behaviors related to neurological and psychiatric disorders. Its president, Per Svenningsson, says that optogenetics "offers opportunities to map the brain".

Portafolio also reports the anecdote of the Secretary General of the Committee, Thomas Perlmann, who first called Deisseroth, "very tired" and probably asleep at the call.

La República adds two of its own readings. The first is financial: each category will receive this year 12 million Swedish crowns, approximately $1.2 million, or one million more than last year (an increase of around 9.1%). Each laureate will receive four million crowns; the Nobel Foundation announced the adjustment on September 18, for the 125th anniversary of the first award. The second is technological: according to a survey by Deutsche Welle relayed by the newspaper, six of the nine artificial intelligence systems questioned were betting on research around GLP-1, against obesity and diabetes, and the committee took "another path".

Berlin, October 6, 2026. The Nobel Prize in Medicine, announced on Monday, October 5, in Stockholm, is presented by the German press as a prize "for two Germans and one American" (DW, FAZ). Peter Hegemann, 71, works at Berlin's Humboldt University, Georg Nagel, 73, at Würzburg University; the American Karl Deisseroth, 54, is at Stanford.

The Tagesschau recounts the genesis as a story of fundamental research: Hegemann wanted to understand how the algae Chlamydomonas reinhardtii orients itself so quickly towards light. Around 2000, new genetic sequences of the algae became public and his team identified genes close to light-sensitive proteins. Nagel, then at the Max-Planck Institute of Biophysics in Frankfurt, introduced these proteins into Xenopus oocytes and showed that one of them, channelrhodopsin-2, is an ion channel directly controlled by light: under blue light, it opens and creates an electrical signal. Deisseroth then transferred the gene into rat neurons, according to DW.

The jury, cited by the FAZ, estimates that the method shows "how nerve cells in the brain form memories, feelings, and behaviors" and that it is used "in laboratories around the world". Abdel El-Manira, from the Karolinska, mentions possible applications for blindness, depression, addiction, or dementia.

In the tagesthemen interview, Hegemann tempers: one can illuminate the brain of a fly or a zebrafish, but the human brain "is largely dark"; a light conductor would need to be placed there, for a volume of one to five square millimeters. The same interview announces that he demands "more courage from politics".

Helsinki, October 6, 2026. In Finland, the announcement of the Nobel Prize in Physiology or Medicine, made on Monday, October 5, in Stockholm, is first treated as a scientific event, explained step by step. The prize goes to American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel for their work on light-activated ion channels and optogenetics.

The most detailed account comes from YLE, which headlines a "revolution in neuroscience" and interviews Eero Castrén, research director at the University of Helsinki's neuroscience center. According to him, the importance of these discoveries for medicine "cannot be exaggerated". YLE reconstructs the chain: Hegemann and Nagel isolated a light-sensitive protein from algae that allows sodium to pass through, then Deisseroth, an American neuroscientist and psychiatrist, obtained a sample of the gene from the German researchers, transferred it into neurons, and showed that they could be activated with precision. Neurons can thus be controlled to the millisecond, and the proteins have since been modified to react to other wavelengths or to turn off cells.

MTV Uutiset highlights a quote from Per Svenningsson, chairman of the Nobel Committee, who says that optogenetics "has allowed us to map the brain in a way we could only dream of before". The channel explains that the method shows how neurons form memories, emotions, and behaviors in a living brain.

Paris, October 6, 2026. The 2026 Nobel Prize in Physiology or Medicine was awarded on Monday, October 5, to American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel, "for their discoveries concerning light-activated ion channels and optogenetics," reports HuffPost France. Le Monde, L'Obs, RFI, and HuffPost quote Per Svenningsson, president of the Nobel Committee for Medicine: a "brain mapping that we could only dream of before."

RFI details the origin of the discovery. Peter Hegemann first sought to understand how the single-celled alga Chlamydomonas swims towards a light source. Georg Nagel identified channelrhodopsin: under blue light, it opens a channel that lets in ions and generates an electrical impulse. Karl Deisseroth introduced his gene into rat neurons, with a publication in 2005, and then, two years later, made the device work in the brain of a living mouse.

The medical angle dominates. Le Monde describes a dual challenge: understanding how the brain forms memories, emotions, and behaviors, but also developing treatments for vision disorders or neurological and psychiatric diseases. In 2021, a first blind patient, suffering from retinitis pigmentosa, a disease that affects nearly two million people worldwide, regained some vision thanks to optogenetic treatment. Ophthalmologist José-Alain Sahel, founder and former director of the Vision Institute in Paris, now in Pittsburgh, who co-directed the trial, welcomes "a very deserved reward that all specialists were waiting for." L'Express also mentions the hope of improving cochlear implants, while Le Monde and HuffPost indicate that the method could one day lead to treatments for Parkinson's and epilepsy.

Rome, October 6, 2026. The Italian press opens the week of the Nobel Prizes with the announcement of the medicine award, announced on Monday, October 5: Karl Deisseroth, Peter Hegemann, and Georg Nagel are being rewarded "for their discoveries related to light-activated ion channels and optogenetics," according to the motivation of the Nobel Assembly of the Karolinska Institutet, as reported by ANSA.

The story prioritizes education. Panorama invites readers to imagine the brain "as a huge electrical network" where one can choose a specific switch, turn it on, turn it off, and immediately observe what changes. The magazine emphasizes the difference between observing that a particular area is activated during an emotion and knowing whether this activity is the cause, consequence, or simply a concurrent phenomenon: optogenetics, it writes, provides a tool to selectively modify the activity of specific neurons with great temporal precision. It sees this as a revolution that, over the past twenty years, has changed the way the brain is studied.

ANSA details the chain of discoveries. Hegemann and Nagel paved the way with the protein called channelrhodopsine, which makes cells sensitive to light when introduced. Deisseroth then transferred the gene into rat neurons and, by exposing them to blue light, triggered a nerve signal. The method is now used in laboratories around the world to understand how the brain organizes emotions and memories.

Seoul, October 6, 2026. The Korea Times and the Korea Herald, which pick up agency dispatches, announce that the 2026 Nobel Prize in Physiology or Medicine was awarded on Monday, October 5, to American Karl Deisseroth, 54, and Germans Peter Hegemann, 71, and Georg Nagel, 73, for their "discoveries concerning light-activated ion channels and optogenetics". The prize, announced at the Karolinska Institute in Stockholm, opens the Nobel week and amounts to 12 million Swedish crowns, or $1.2 million.

The Korea Herald details the scientific chain: Peter Hegemann explores how a single-celled green alga swims towards light; with Georg Nagel, he discovers a protein that, when exposed to blue light, opens a channel and creates an electrical impulse. Karl Deisseroth then uses the gene of this protein to manufacture a light switch for the neurons of living mice. Thomas Perlmann, Secretary General of the Nobel Assembly, states that the method "is used in laboratories around the world to reveal the mysteries of the brain".

The Korea Times emphasizes the clinical applications. Trials restore vision to people blinded by retinitis pigmentosa thanks to a light-sensitive protein inserted into the retina, and researchers hope for more precise cochlear implants than current electronic devices. According to the newspaper, Karl Deisseroth, who also practices as a psychiatrist, mentions hope for patients with autism and depression.

Mexico, October 6, 2026. Mexican media is covering the awarding of the Nobel Prize in Physiology or Medicine to American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel on Monday, October 5, from the angle of how the technique is changing the understanding of the brain.

El Financiero reports on a jury that distinguished three researchers "for having opened a new era in neuroscience". The economic daily highlights the explanation of memories: optogenetics shows how nerve cells form memories, feelings, and behaviors. It lists the functions illuminated by the method: the sensation of pain, social behaviors, thirst, food, attention, circadian rhythms, and even fever triggered by the immune system.

Vanguardia MX uses the metaphor of a switch in its title. The newspaper describes a technique that activates or deactivates precise groups of neurons through light stimuli, which has allowed for more precise observation of the role of circuits in memories, emotions, movements, and states of wakefulness. It recalls the award of 12 million Swedish crowns, shared equally among the three laureates.

Both titles quote Per Svenningsson, president of the Nobel Committee: optogenetics offers "possibilities to map the brain like we could only dream of". El Financiero adds the words of medical genetics professor Anna Wedell on a "giant step": we had anatomical maps, we can now produce functional maps and understand how different cells communicate.

Lima, October 6, 2026. The official Andina agency and the economic daily Gestión cover the 2026 Nobel Prize in Physiology or Medicine in almost identical terms, both constructed from the text of the announcement made on Monday, October 5, from Stockholm. The prize goes to American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel "for their discoveries on light-activated ion channels and optogenetics," according to the Nobel Assembly of the Karolinska Institute.

The two headlines present optogenetics as a method that shows how nerve cells shape memories, feelings, and behaviors in the living brain. They quote the jury, which says these works "have laid the foundation for a new era in neuroscience." They also repeat the jury's phrase that optogenetics "has radically transformed our understanding of the brain," with new discoveries every day about "one of the great mysteries of humanity."

The medical dimension is the most emphasized. Thanks to this technique, researchers have been able to uncover the neural circuits that control memories, emotions, and behaviors related to neurological and psychiatric disorders. The articles add that in clinical medicine, researchers are using it to try to restore vision in people with visual impairments.

Islamabad, October 6, 2026. Business Recorder, ARY News, and Geo News are covering the Nobel Prize in Physiology or Medicine awarded on Monday, October 5, to American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel, for their "discoveries concerning light-activated ion channels and optogenetics".

Business Recorder, from Stockholm, quotes Thomas Perlmann, Secretary General of the Nobel Assembly at the Karolinska Institute: the method "allows for the activation or deactivation of individual nerve cell activity in a living brain" and is now used "in laboratories around the world". Anna Wedell, a committee member, sees this as the beginning of a "new era" for neuroscience, while specifying that it is only a start. The three laureates share 12 million Swedish crowns, equivalent to $1.2 million. The newspaper recalls the origin of the work: in the early 1990s, Hegemann studied the reaction of the alga Chlamydomonas to light, then Nagel identified channelrhodopsin-2 by injecting alga genes into frog oocytes.

ARY News publishes an AFP dispatch dated October 6, which emphasizes the applications: optogenetics could lead to advances against dementia, depression, and blindness. Simon Schultz, a professor at Imperial College London, believes that manipulating cells with light and genetics has been "transformative" for biological sciences. His team has used it as a closed-loop treatment for memory disorders, and the next step would be to improve learning and memory in complex tasks. The text also mentions blindness, with Jose-Alain Sahel.

Belgrade, October 6, 2026. Serbian media covered the Nobel Prize in medicine in two stages. On Monday, October 5, Beta announced that the prize went to Karl Deisseroth (54 years old), Peter Hegemann (71 years old), and Georg Nagel (73 years old), "for research on light-controlled ion channels" and for the development of optogenetics. The first works at Stanford University in California, the second at Humboldt University in Berlin, and the third in Wurtzbourg. Beta recalled that the Nobel Committee judged their method "used today in laboratories around the world to uncover the mysteries of the brain".

The next day, Tuesday, October 6, N1 Serbia, Politika, and Beta published the same dispatch from the AP agency, under the title "The new Nobel laureate interrupted congratulations to prepare his children's snack". The text described Deisseroth, who calls himself a "night owl", re-reading papers and responding to emails from his students on Sunday evening, before being called from Stockholm. "I was almost speechless," he told AP, before regaining his composure after a minute or two and not going back to bed.

The dispatch lingered on the details of the night. An AP photographer arrived around 3:30 am in front of the Stanford home, where Halloween decorations adorned the entrance and only one lamp was lit. He feared he had gotten the wrong address. Dr. Michelle Monje-Deisseroth, the laureate's wife, a researcher at HHMI and a pediatric neuro-oncologist at Stanford, opened the door. Her husband, sitting on the couch, received congratulations. She prepared coffee for the Stanford communications team that had arrived on the scene.

Stockholm, October 6, 2026. The Nobel Prize in Physiology or Medicine, announced on Monday, October 5, goes to American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel "for their discoveries concerning light-activated ion channels and optogenetics," writes Dagens Nyheter. The three laureates share 12 million crowns, notes Expressen, which points out that the Nobel Foundation increased the amount by one million.

The Swedish press first explains the mechanics. Sveriges Radio talks about a "light switch for nerve cells." Dagens Nyheter and Expressen tell the story of how it began: Peter Hegemann wondered in the 1990s how the green alga Chlamydomonas could swim towards light, with the reaction in its eye spot taking half a millisecond. Along with Georg Nagel, he identified channelrhodopsine, and then Karl Deisseroth introduced the gene into rodents and the brains of living mice.

Nobel Committee President Per Svenningsson is quoted by several titles: "Optogenetics has given us the means to map the brain like we never could before." Svenska Dagbladet adds a personal portrait, with journalist Therese Bergstedt describing a Deisseroth she met in Stockholm in 2015 as "shy and modest."

The medical angle dominates the news articles. Aftonbladet and Svenska Dagbladet give the floor to Merab Kokaia, from the Lund epilepsy center, who has collaborated with Deisseroth, an honorary doctor at Lund University, for a long time. He judges the technique to have "great potential" against epilepsy seizures, but notes that it works in mice and rats and has not yet been tested in humans. For Parkinson's and depression, "it will take time"; current clinical trials are targeting vision.

London, 6 October 2026. The British press presents the 2026 Nobel Prize in Physiology or Medicine, announced on Monday, 5 October, as a reward for having "revealed the internal functioning of the brain". The BBC focuses on American Karl Deisseroth, a psychiatrist and neurologist, and Germans Peter Hegemann and Georg Nagel, distinguished for optogenetics.

The British narrative relies heavily on the words of the Nobel Assembly. The Assembly states that the method has laid "the foundations for a new era in neuroscience" by showing how to activate or cut off neural circuits related to specific "memories, feelings, and behaviors", useful for neurological and psychiatric disorders. Per Svenningsson, chairman of the Nobel Committee, sees it as a way to map the brain "like we could only dream of before". The Assembly adds: "Every day brings new discoveries."

The BBC explains the technique to the general public: a protein borrowed from algae, which researchers use to control the electrical activity of cells with light. It specifies that Hegemann and Nagel uncovered, in the early 2000s, the light-sensitive channels. The text notes that before this, the mechanisms behind emotions, behaviors, and bodily functions remained largely a mystery.

The only medical application highlighted is vision: according to the BBC, researchers are using the method to try to restore it in blind people. The Independent, on the other hand, repeats the formula of the committee that optogenetics "allows you to turn on or off the activity of individual nerve cells in a living brain", and emphasizes its use "in laboratories around the world".

Washington, October 6, 2026. The Nobel Prize in medicine, announced on Monday, October 5, is presented by the American press as that of a tool: the Associated Press speaks of "a tool that uses light to help unravel how the brain works." Karl Deisseroth, 54, a researcher at the Howard Hughes Medical Institute and professor at Stanford (California), shares the award with Germans Peter Hegemann, 71, from Humboldt University in Berlin, and Georg Nagel, 73, who last worked at the University of Würzburg.

ABC News, HuffPost, and NPR detail the scientific journey. Everything starts with Hegemann, who studies how a single-celled green alga swims towards light. With Nagel, he isolates a protein that, when illuminated in blue, opens a channel and creates an electrical impulse; introducing it into other cells makes them sensitive to light. Deisseroth then works on the gene of this protein to manufacture a light switch for neurons, in the brains of living mice. The Nobel Assembly sees "a new era in neuroscience": the tool begins to unravel the pathways that lead to behavior and disease.

The American narrative gives a place to public funding. Jeremy Berg, from the University of Pittsburgh, recalls that he was at the National Institutes of Health in the early 2000s, when the agency awarded Deisseroth significant funding for "this vision of optogenetics," which unfolded almost exactly as planned. He judges the tool "very precise" for experiments on brain function "pretty hard to do any other way." Deisseroth, who claims to be a night owl, was up late for the announcement, according to HuffPost, and summarizes: "People usually think about light as a way of collecting information to observe things," whereas this method does the opposite.

Montevideo, October 6, 2026. Uruguayan media reported as early as Monday, October 5, the awarding of the 2026 Nobel Prize in Medicine to American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel. Subrayado headlines a prize awarded "to an American and two Germans for advances in optogenetics". El Observador specifies that the Nobel Assembly of the Karolinska Institute distinguished them "for their discoveries on light-activated ion channels and optogenetics".

The Uruguayan account emphasizes the use of the technique. Subrayado presents it as a discipline that allows us to understand how certain cells contribute to learning, fear, addiction, and movement. The two media outlets quote the Nobel Committee: thanks to optogenetics, researchers have been able to "reveal the neural circuits that control specific memories, feelings, and behaviors" related to neurological and psychiatric disorders. They also repeat the committee's phrase that this method "has radically transformed our understanding of the brain".

The medical scope is posed in the conditional. Subrayado writes that these works "could one day lead to treatments" for neurological and sensory disorders, such as Parkinson's disease and epilepsy. El Observador adds, under a subheading on medical applications, that researchers are already using the method in clinical medicine to try to restore the vision of visually impaired people. Neither of the two articles provides a timeline for these treatments.

Pretoria, October 6, 2026. TimesLIVE and Business Day published the same story on Monday, October 5: American Karl Deisseroth and Germans Peter Hegemann and Georg Nagel won the 2026 Nobel Prize in Physiology or Medicine for optogenetics, "a technique that uses light to control individual nerve cells in the brain".

The Nobel Assembly at the Karolinska Institute selected them for their "discoveries concerning light-activated ion channels and optogenetics". Deisseroth is 54 years old, Hegemann 71 years old, and Nagel 73 years old. The two articles specify that the three laureates share 12 million Swedish crowns, converted for local readers to "R20m", twenty million rands.

The story emphasizes scientific progress. In the early 1990s, Hegemann studied the reaction of the alga chlamydomonas to light, "in half a millisecond", and hypothesized that a single protein captures light and acts as an ion channel. Nagel tested this idea by injecting chlamydomonas genes into frog eggs and discovered channelrhodopsine-2, a light-sensitive ion channel. In 2003, they published that this protein can be introduced into human and hamster cells to produce electrical impulses through light.

At Stanford, Deisseroth demonstrated the technique on rat neurons two years later, and the method was named optogenetics in 2006. The articles also cite its use to control the movements of a mouse's whiskers by activating neurons in the motor cortex.